This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

Teva faces $2 billion damages for selling generic Protonix


Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.

Teva, Pfizer, Nycomed, Protonix, generic, damages


Payment types accepted